Maria Moscvin (@MMoscvin) ranks #42 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 3 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: KEYNOTE-671. This profile quotes their 1 trial post from 2026 word for word, with links to the originals on X.
At a Glance
- 1 posts naming a trial in 2026
- 1 trials discussed by name
- Lung Cancer: US #42 · 3 physicians engaged
This Month
What Maria Moscvin has posted in the last 30 days. Updated November 10, 2026.
Another presentation Dr. @marinagarassino from @UCCancerCenter @UChicagoMed with biomarker analysis of KEYNOTE-671 for resectable early stage NSCLC. https://t.co/7urBmqr9iR
Who Amplifies Maria Moscvin
Physicians who reposted Maria Moscvin’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #42 | — | 3 | 3 | Full ranking |
Trials Maria Moscvin Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| KEYNOTE-671 | 1 | #4 of 13 | Oct 26, 2026 |
Maria Moscvin on KEYNOTE-671
Another presentation Dr. @marinagarassino from @UCCancerCenter @UChicagoMed with biomarker analysis of KEYNOTE-671 for resectable early stage NSCLC. https://t.co/7urBmqr9iR
Maria Moscvin’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Our own @marinagarassino @UCCancerCenter @UChicagoMed chair of the Thymic Tumors state of the art and addition of Ivonescimab in TC 1L and Rivoceranib Thymoma/TC further lines https://t.co/zlAztBvENB
Kicking off #ESMO2026 with Alessandra Pedrocchi explaining the safety brakes we need to generate before employing AI agents in oncology https://t.co/Q1flHp6Kau